Announcement on Implementation Results of the 4th Share Repurchase and Share Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Implementation Results of the 4th Share Repurchase and Share Changes
Filed with SSE ·
On 6ix: 6ix.com/news/announcement-on-implementation-results-of-the-4th-share-repurchase-and-share-changes
6ix hasn’t read this filing yet.
Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Hisun Pharmaceutical
- Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
- Correction Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right
- Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary
- Announcement on the Obtainment of CEP Certificate for Ticagrelor Active Pharmaceutical Ingredient
- Announcement on Lifting Trading Restrictions in the 3rd Trade Restriction Release Period for Reserved Granted Parts under 2021 Restricted Stock Incentive Plan and Stock Marketing
Later from Zhejiang Hisun Pharmaceutical
- Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug
- Announcement on Convening the 2025 Annual Performance Briefing
- Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
- Announcement on Estimated Daily Related Party Transactions in 2026
- Announcement on Preliminary Earnings Estimate for Q1 2026
Follow Zhejiang Hisun Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Hisun Pharmaceutical